This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that Kadcyla (ado-trastuzumab emtansine) be approved as an adjuvant (post-surgery) treatment for certain HER2-positive early breast cancers, the treatment’s maker, Genentech, has announced. Specifically, the advisory committee for the European Union’s…

This post was originally published on this site Treatment with Myovant Sciences’ relugolix induces a long-lasting reduction in testosterone to castrate levels — similar to testosterone levels after medical or chemical castration — in nearly all men with advanced prostate cancer who are sensitive to androgen deprivation therapy, updated results from the HERO Phase 3…

This post was originally published on this site STRO-002, an investigational antibody-drug conjugate being developed by Sutro Biopharma, is safe and shows promising efficacy in women with advanced ovarian, fallopian tube, or primary peritoneal cancer, early Phase 1 clinical data show. The findings were presented during the recent AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference…

This post was originally published on this site Early treatment with a triple combination therapy containing Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone in patients with high-risk smoldering multiple myeloma — a precursor of multiple myeloma — is safe and may halt the disease’s progression into the full-blown condition, a Phase 2 trial shows. The results will…

This post was originally published on this site A branch of the European Medicines Agency voiced support for Revlimid (lenalidomide) in combination with rituximab becoming a treatment option for adults with follicular lymphoma who responded poorly to, or whose disease returned after, prior therapy. The Committee for Medicinal Products for Human Use (CHMP), an advisory committee for the…

This post was originally published on this site High blood levels of two hormones — insulin-like growth factor-I (IGF-I) and free testosterone — are associated with increased risk of prostate cancer later in life, a new study suggests. The study, “Serum hormones and prostate cancer incidence and mortality in UK Biobank,” was presented at the recent 2019 National…

This post was originally published on this site The Italian Medicines Agency (AIFA) has approved Clovis Oncology’s Rubraca (rucaparib) for reimbursement in Italy as a maintenance therapy for women with relapsed ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA status. This follows Rubraca’s approval for that indication by the European Commission early this year.…

This post was originally published on this site Venclexta (venetoclax), approved to treat lymphoma and leukemia, may also be promising for multiple myeloma patients who failed at least one prior treatment, particularly those with a common genetic abnormality called t(11;14) or with high levels of the cell survival protein BCL2, data from two studies suggest. Findings…

This post was originally published on this site First-line maintenance therapy with Bavencio (avelumab) failed to extend the overall survival of patients with advanced stomach or gastroesophageal junction (GEJ) cancer, as compared to standard care, according to the latest updates of the JAVELIN Gastric 100 clinical trial. The study was a Phase 3, multicenter, open-label…

This post was originally published on this site Weight loss surgery may reduce the risk of developing breast cancer in obese individuals, even among those with a genetic predisposition towards cancer, new research suggests. The research was presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting at ObesityWeek 2019, in a…

This post was originally published on this site Combination treatment with Ygalo (melflufen) continues to be safe and effective in difficult-to-treat patients with relapsed or refractory multiple myeloma (RRMM), according to the latest results from clinical trials. Data from the clinical program of Ygalo and multiple myeloma’s impact on quality of life will be presented…

This post was originally published on this site Intermediate monocytes, a type of immune cell, may contribute to the development and progression of sarcoidosis through the production of TARC — a molecule that attracts other specific immune cells linked to inflammation, according to a small study. These findings point to intermediate monocytes and TARC as…